Prior authorization in gastroenterology: capsule endoscopy, biologics, and ERCP.
Three service lines drive nearly all of gastroenterology's prior-auth denial volume — capsule endoscopy, IBD biologic infusions, and ERCP — and each one fails for a different, specific reason. Capsule endoscopy denies for missing prior-attempt documentation. Biologic infusions deny for step-therapy detail that's stated too vaguely. ERCP denies when elective and emergent get confused at scheduling. This guide covers the exact documentation each one needs and where Aetna, UnitedHealthcare, and Cigna diverge.
Key takeaways
- Capsule endoscopy is second-line, not a substitute, everywhere it's covered. Every MAC coverage article we checked and Cigna's own clinical guideline require a documented prior colonoscopy or EGD attempt — or a specific contraindication — before capsule is authorized.
- "Failed prior biologic" isn't documentation — dates, doses, and the reason for discontinuation are. UnitedHealthcare's infliximab biosimilar policy names a specific trial length (14 weeks) before a non-preferred product is approved; vague step-therapy notes get requests returned, not approved.
- Elective versus emergent decides whether ERCP needs prior auth at all — not the CPT code. Confirm which category a case falls into at scheduling, because adding an authorization after an elective claim is submitted is far harder than getting it first.
- Most commercial GI prior auth runs through a delegated vendor, not the payer directly — Cigna's capsule endoscopy and EGD reviews route through eviCore, for example, which has its own portal and its own clinical guideline documents separate from Cigna's general medical policy.
Capsule endoscopy: the prior-attempt requirement
Capsule endoscopy has three relevant codes — 91110 (esophagus through ileum), 91111 (esophagus only), and 91113 (colon capsule) — and prior authorization is close to universal across Medicare Advantage and commercial plans for all three. The single documentation requirement that decides most of these requests: a standard colonoscopy or EGD has to have been attempted and found incomplete, or specifically contraindicated, before capsule is authorized. It is treated as second-line, not an alternative to be chosen up front.
- 1Prior conventional exam attempted and incomplete. The operative note has to state why — poor prep, patient intolerance, anatomic obstruction, failure to reach the target segment — not just "colonoscopy performed."
- 2Or a specific, named contraindication. A general statement like "patient prefers capsule" or "patient declined colonoscopy" is a standing denial trigger; the contraindication has to be clinical (e.g., a bleeding risk from anticoagulation that can't be interrupted, a structural reason conventional scope access failed) and documented in the chart, not inferred.
- 3Matching indication on the authorization request. Obscure GI bleeding with iron deficiency anemia (
D50.0) or melena (K92.1) are common, well-supported indications for capsule study when a prior EGD and colonoscopy were negative or incomplete — state the indication and the prior workup together, not the indication alone.
Commercial review for capsule endoscopy is frequently delegated. Cigna, for example, routes gastroenterology prior authorization — including capsule endoscopy and EGD — through eviCore's own portal and clinical guideline documents, which are separate from Cigna's general medical policy pages. Confirm which vendor actually adjudicates the request for a given payer before assuming the payer's own prior-auth process applies. ⚠️ This detail was confirmed through eviCore's own published Cigna gastroenterology guideline documents found via web search, not through direct access to Cigna's provider portal during this build — verify current delegation and portal details for your specific payer contract before building a workflow around it.
IBD biologic and infusion step therapy
Entyvio (vedolizumab) and biosimilar infliximab (Inflectra, Avsola, Renflexis, and brand Remicade) authorizations run on step therapy, and the documentation has to be specific — dates, doses, duration, and the clinical reason a prior therapy was discontinued, not a summary statement that treatment "failed."
| Payer | Drug | What the policy requires |
|---|---|---|
| Aetna | Entyvio (vedolizumab) | Precertification under Clinical Policy Bulletin 0885, updated August 2026; requires diagnosis, prescriber specialty (gastroenterologist for IBD indications), loading and maintenance dosing schedule, and evidence of clinical response for continuation requests — not just initial approval |
| UnitedHealthcare | Infliximab biosimilars | Non-preferred biosimilar or brand Remicade requires documentation of at least a 14-week trial of a preferred biosimilar (Inflectra or Avsola) with minimal clinical response before approval |
| Cigna (via eviCore) | Biologic infusions generally | Gastroenterology-specific clinical guidelines administered through eviCore's portal, distinct from Cigna's general medical drug policy — confirm the specific eviCore guideline document for the drug in question rather than relying on Cigna's general formulary language |
The documentation pattern that gets a request approved on the first pass: name the specific prior agent, the start and stop dates, the dose and route, and the specific reason for discontinuation — inadequate response, loss of response after initial benefit, or intolerance (and if intolerance, the specific adverse event). A note that says only "failed adalimumab" gives the reviewer nothing to check against the payer's step-therapy criteria and is a common reason the request comes back for more information rather than a denial outright — which still delays the first infusion and the revenue tied to scheduling it. Diagnosis specificity helps here too: a location-and-complication-specific Crohn's code like K50.013 (Crohn's disease of small intestine with fistula) supports a biologic escalation request more directly than the unspecified K50.90, because it documents exactly why step therapy needs to move forward.
Build a standing step-therapy documentation template into the chart at the point a biologic is first considered — drug name, start date, stop date, dose, and discontinuation reason — rather than reconstructing it from scattered visit notes when the prior-auth request goes out. It cuts the single most common cause of a returned-for-more-information request in this category.
ERCP and advanced imaging: elective versus emergent
Elective ERCP — scheduled for a known stricture, suspected choledocholithiasis without acute obstruction, or a planned stent exchange — is the norm requiring prior authorization across commercial and Medicare Advantage plans. A genuinely emergent ERCP, for acute cholangitis or an acutely impacted common bile duct stone, typically doesn't need authorization before the procedure, though most payers still expect notification within a defined window afterward. The distinction that decides whether a claim needs an authorization number on it is elective versus emergent clinical status, not which CPT code from the 43260–43278 family gets billed.
Cross-sectional imaging that frequently precedes ERCP — MRCP, CT abdomen/pelvis with contrast — typically carries its own separate prior-authorization requirement through a radiology benefit manager, which is a different authorization process and a different vendor than the one covering the ERCP itself. Confirm both authorizations exist independently before the ERCP is scheduled; an approved ERCP authorization does not retroactively cover the imaging that led to it, and vice versa.
Do and don't
- Document the prior colonoscopy/EGD attempt and outcome before requesting capsule endoscopy authorization.
- Capture drug, dates, dose, and discontinuation reason for every prior biologic at the point of discussion, not at prior-auth time.
- Confirm elective versus emergent status for ERCP at scheduling, and get both the imaging and the ERCP authorization independently.
- Confirm which vendor (payer direct or a delegated reviewer like eviCore) actually adjudicates the request for that specific payer.
- Don't submit a capsule endoscopy request citing only a general indication without the prior-attempt or contraindication note.
- Don't summarize step therapy as "failed prior biologic" without dates, dose, and the specific reason for discontinuation.
- Don't assume an approved ERCP authorization also covers the MRCP or CT that preceded it.
- Don't wait for a payer's general medical policy page when a delegated vendor's own clinical guideline actually governs the request.
Losing revenue to prior-auth delays and denials?
We'll build the specific documentation checklist your practice needs for capsule endoscopy, biologic infusions, and ERCP by payer, and track every authorization before the claim goes out.
Frequently asked questions
What has to be documented before a capsule endoscopy prior auth request goes out?
A prior colonoscopy or EGD that was attempted and was incomplete, or a specific, documented contraindication to conventional endoscopy — not a general indication or a statement that the patient prefers capsule. Every MAC that publishes a colon capsule endoscopy coverage article treats it as second-line behind conventional endoscopy, and Cigna's clinical guidelines for capsule endoscopy carry the same requirement for commercial coverage through eviCore. Get the prior attempt or contraindication note into the chart and the authorization request before scheduling the capsule study, not after a denial.
How much biologic step therapy documentation does an IBD infusion authorization actually need?
Specific dates, doses, and duration of the prior therapy, plus the clinical reason it was discontinued — inadequate response, loss of response, or intolerance — not just a note that a prior therapy "failed." UnitedHealthcare's infliximab biosimilar policy, for example, requires documentation of at least a 14-week trial of a preferred biosimilar before a non-preferred product is approved. A request that states "failed prior biologic" without dates, doses, and the specific reason for discontinuation is a standing cause of a request being returned for more information rather than approved on the first pass.
Does every payer require prior authorization for ERCP?
Elective ERCP is the norm requiring authorization across commercial and Medicare Advantage plans; a genuinely emergent ERCP for acute cholangitis or an impacted common bile duct stone typically does not need one before the procedure, though most payers still want notification after the fact. The distinction that matters operationally is elective versus emergent, not the CPT code billed — confirm which category the case falls into at scheduling, because retrofitting an authorization onto a claim that already went out as elective is far harder than obtaining it before the case.
Verify before billing. CPT is a registered trademark of the American Medical Association; codes here are paraphrased, not reproduced from the CPT Professional edition. CPT, HCPCS and ICD-10 codes, coverage policy, and bundling edits change, including annual code-set updates. This page reflects standard industry practice and is provided for general education — it is not a substitute for your own compliance review, your current payer contracts, or the current-year code sets. Confirm requirements against your specific payer mix before submitting claims.